Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
about
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionAmphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropeniaEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents.Lipid-based amphotericin B for the treatment of fungal infections.Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patientsPharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.Serum pharmacology of amphotericin B applied in lipid emulsions.Carrier effects on biological activity of amphotericin B.Antifungal prophylaxis during neutropenia and immunodeficiencyIncidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic CriteriaCombination therapy for mucormycosis: why, what, and how?Liposomal amphotericin B: clinical experience and perspectives.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.Mucormycosis in two community hospitals and the role of infectious disease consultation: a case series.State of the art review: Intravenous fat emulsions: Current applications, safety profile, and clinical implications.Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patientsEfficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion.Amphotericin B toxicity reduced by administration in fat emulsion.The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu.Intralipid in prophylaxis of amphotericin B nephrotoxicity.Development of liposomal amphotericin B formulation.Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.New agents for the treatment of systemic fungal infections--current status.Amphotericin B is incompatible with lipid emulsions.
P2860
Q24187699-EFC49E2C-7D0A-4A3C-920A-BB8AE9494B5CQ24193811-2B8511E5-4332-4896-9F13-FA4B4B5D2CE1Q30240770-02B3074A-47AD-4959-987A-C1C4A0EBB61AQ30887348-42D90E0D-2E66-4300-A28D-3E85425711F2Q32052950-EDF387A7-A693-403C-869B-663B0196B850Q33253851-C92D9A2F-7029-437E-8354-485439523CD1Q33604227-57C9BB37-917F-48C3-9F66-975E42220EFAQ33692176-5710E0E7-1AC0-482E-8EF7-B7A84E803A0CQ33824631-41EC7B1F-F295-4A10-8F80-E9BC5EFC896AQ33976955-87D78109-D1D8-4657-88E2-AF1EBEBC8C35Q35122944-F8FDE74B-C6C4-4A75-B1AB-782451165BADQ35134565-3B2EA93F-9B9D-46B8-975B-F08CE840BEA0Q35372581-58E23F7E-E6B5-46DC-BB00-A937A0E4E618Q35374928-D4D3121F-03CA-472E-9EC1-DFF1DD43E064Q35860053-FD143B49-2C49-41B5-BC31-F138C90E0D3FQ35974333-C1113BCC-D49F-4DF3-B715-35C898ABE94BQ36140647-721FED36-CA7C-4674-8ACF-4D8BD6412E43Q36407276-F62DA220-AABF-4111-8090-8C69261D68A2Q36519575-9846C5BF-A127-43C2-BA65-BCEADD69EF08Q37278607-D3970DE9-4F61-4D0A-8243-C1B5C7871B9FQ37717898-CC1B968C-5369-471D-822D-6BC9A051DA90Q38077678-6479FC6E-F0C5-47CA-AD61-E5496BF2752BQ39470922-868D55EA-4418-4139-8902-E3F303C0A2DCQ39866778-6C84D760-F191-422A-BF06-A125750179F8Q40043040-0C937396-9E53-4621-8503-2514FE4C9C91Q40286515-6DD51496-7E81-4DD2-913E-C4F50A4A0DCEQ40471190-7F1D759F-3FAB-48B6-ABFA-84B8DDD06195Q40499103-18EE9381-FB87-42E4-BF92-39A8B0991163Q40582560-85C85BBF-2CF2-47C9-A527-5711254EC514Q40639958-7BD1ABB8-8A7A-412A-B46A-27EDCDB7CB21Q40677144-E0A80620-EF36-461F-8A7F-2BD7CAC89EB2Q43102684-2A6589A3-D7A2-4E30-92BE-57886E345530Q46576615-49E0A669-E770-48D2-9004-A297B2B3F01EQ54122029-27427A75-3349-4F27-ADD4-B28B33FC657B
P2860
Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Reduced renal toxicity and imp ...... cin B in neutropenic patients.
@en
type
label
Reduced renal toxicity and imp ...... cin B in neutropenic patients.
@en
prefLabel
Reduced renal toxicity and imp ...... cin B in neutropenic patients.
@en
P2093
P356
P1476
Reduced renal toxicity and imp ...... cin B in neutropenic patients.
@en
P2093
P304
P356
10.1093/JAC/30.4.535
P407
P577
1992-10-01T00:00:00Z